文献速递免疫规划

季节性三价灭活流感疫苗联合新型水包油佐剂/递送系统MAS-1的1期剂量节省随机临床试验

A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
PubMed 文献 · Vaccine · 2022-02-04

这项1期双盲随机临床试验纳入72名18-47岁受试者,比较MAS-1佐剂联合1、3、5或9 µg血凝素(HA)与标准剂量灭活流感疫苗(15 µg HA)的安全性及免疫原性。结果显示MAS-1佐剂组在全部HA剂量下血凝抑制抗体应答普遍更高且持续时间更长(至第169天),未发现安全性问题,提示其具有HA剂量节省效应。

要点

  • MAS-1佐剂联合1-9 µg HA在全部剂量下抗体应答普遍高于标准剂量疫苗。
  • 佐剂组抗体应答持续时间更长,至第85天和第169天访视仍较高。
  • 常见反应为轻度压痛、硬结、疼痛、头痛、肌痛等,14天内消退。

核心结论

  • 0.3 mL MAS-1佐剂提供HA剂量节省效应且无安全性担忧,诱导更高的血凝抑制抗体和血清转化应答至少持续6个月,显示在年轻成人中有望在整个流感季节提供更大疫苗效力。
  • MAS-1可能提供比非佐剂标准剂量灭活流感疫苗更强、更持久和更广的保护性免疫。

研究设计与样本

  • 1期双盲、安全性和免疫原性、HA剂量递增随机临床试验。
  • 72名18-47岁受试者接受单剂0.3 mL佐剂疫苗或标准剂量灭活流感疫苗肌肉注射。
  • 佐剂组HA剂量为1、3、5或9 µg,源自许可的季节性三价高剂量灭活流感疫苗(Fluzone HD,每HA 60 µg)。
  • 对照为标准剂量灭活流感疫苗(Fluzone SD,每HA 15 µg)。

主要发现

  • 常见注射部位和全身反应为轻度压痛、硬结、疼痛、头痛、肌痛、不适和疲劳,所有反应在接种后14天内消退。
  • 安全性实验室指标组间无差异。
  • 针对疫苗株的几何平均抗体滴度、几何平均抗体滴度增长倍数、血清转化率和血清保护率,MAS-1佐剂灭活流感疫苗在所有HA剂量下普遍更高且持续时间更长(第85天和第169天访视)。
  • 佐剂疫苗对有限数量的非研究疫苗流感B型和A/H3N2病毒(包括后续年份的病毒)诱导更高的抗体应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New influenza vaccines are needed to increase vaccine efficacy. Adjuvants may allow hemagglutinin (HA) dose-sparing with enhanced immunogenicity. MAS-1 is an investigational low viscosity, free-flowing, water-in-oil emulsion-based adjuvant/delivery system comprised of stable nanoglobular aqueous droplets. METHODS: A phase 1, double-blind, safety and immunogenicity, HA dose escalation, randomized clinical trial was conducted. MAS-1 adjuvant with 1, 3, 5 or 9 µg per HA derived from licensed seasonal trivalent high dose inactivated influenza vaccine (IIV, Fluzone HD 60 µg per HA) in a 0.3 mL dose were compared to standard dose IIV (Fluzone SD, 15 µg per HA). Safety was measured by reactogenicity, adverse events, and clinical laboratory tests. Serum hemagglutination inhibition (HAI) antibody titers were measured for immunogenicity. RESULTS: Seventy-two subjects, aged 18-47 years, received one dose of either 0.3 mL adjuvanted vaccine or SD IIV intramuscularly. Common injection site and systemic reactions post-vaccination were mild tenderness, induration, pain, headache, myalgia, malaise and fatigue. All reactions resolved within 14 days post-vaccination. Safety laboratory measures were not different between groups. Geometric mean antibody titers, geometric mean fold increases in antibody titer, seroconversion rates and seroprotection rates against vaccine strains were in general higher and of longer duration (day 85 and 169 visits) with MAS-1-adjuvanted IIV at all doses of HA compared with SD IIV. Adjuvanted vaccine induced higher antibody responses against a limited number of non-study vaccine influenza B and A/H3N2 viruses including ones from subsequent years. CONCLUSION: MAS-1 adjuvant in a 0.3 mL dose volume provided HA dose-sparing effects without safety concerns and induced higher HAI antibody and seroconversion responses through at least 6 months, demonstrating potential to provide greater vaccine efficacy throughout an influenza season in younger adults. In summary, MAS-1 may provide enhanced, more durable and broader protective immunity compared with non-adjuvanted SD IIV. Clinical Trial Registry: ClinicalTrials.gov # NCT02500680.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gorse GJ, Grimes S, Buck H, et al. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system. Vaccine. 2022. PMID: 35125219. doi:10.1016/j.vaccine.2022.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。